查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1845957

Sorafenib市場規模：按產品、應用和地區分類的範圍和預測

Sorafenib Market Size By Product (Patented Drugs and Generic Drugs), By Application (Kidney Cancer, Liver Cancer, Thyroid Cancer, Other), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

Sorafenib市場規模及預測

預計Sorafenib市場在 2024 年的價值將達到 11.1 億美元，並在 2031 年達到 12.1 億美元，2024 年至 2031 年的複合年成長率為 1.21%。

Sorafenib主要用於治療腎癌、甲狀腺癌和肝癌。流行病學研究表明，過去幾十年來甲狀腺癌的發生率一直在上升。Sorafenib市場報告對市場進行了全面的評估，包括關鍵細分市場、趨勢、市場促進因素、限制因素、競爭格局以及影響市場的關鍵因素。

定義全球Sorafenib市場

Sorafenib是一種分子標靶抗癌藥物，其作用機制是抑制多種被認為參與細胞增殖（生長）和血管生成（血液供應）的激酶。Sorafenib最初開發用於治療無法切除的肝細胞癌 (HCC)、進行性腎細胞癌以及對放射性碘治療無效的局部復發或轉移性進行性分化型甲狀腺癌患者。

這種口服激酶抑制劑可有效調節多種蛋白激酶和訊號通路，包括訊號傳導和轉錄活化因子3 (STAT3)、血小板衍生生長因子受體 (PDGFR) 和血管內皮生長因子受體2 (VEGFR-2)。Sorafenib也用於治療肝癌和甲狀腺癌。該藥物是晚期肝細胞癌 (HCC) 的一線治療藥物。

然而，自2007年獲得FDA核准以來，Sorafenib治療在腫瘤學實踐中並未廣泛應用。Sorafenib已知有副作用，包括出血、高血壓、皮膚毒性、心肌缺血/梗塞、胃腸道穿孔、藥物性肝炎和創傷治療併發症。此外，多項研究發現Sorafenib產生獲得性抗藥性，降低了其在腫瘤學領域的臨床意義。因此，Sorafenib常與其他用於治療肝細胞癌的細胞毒藥物聯合治療使用，產生協同抗癌活性。

全球Sorafenib市場概覽

癌症仍然是全球主要死亡原因之一。癌症新發病例數持續成長。癌症是一個重大的公共衛生問題，目前被認為是一種潛在的慢性疾病。早期診斷和治療的進步顯著提高了癌症患者的存活率。

Sorafenib主要用於治療腎癌、甲狀腺癌和肝癌。流行病學調查結果顯示，過去幾十年來甲狀腺癌的發生率持續上升。高所得國家甲狀腺癌的發生率顯著上升，全球甲狀腺癌的年齡標準化發生率上升了約20%。同樣，隨著肝癌和腎癌患者的快速成長，預計對Sorafenib等抗癌藥物的需求也將增加。

科學家們正在嘗試挖掘奈米技術的潛力，以提高Sorafenib的靶向性和生物有效性。基於Sorafenib的奈米遞送系統能夠控制藥物釋放，進而提高抗腫瘤療效。同樣，各種研究也正在進行中，旨在結合聚合物膠束的應用來增強Sorafenib的抗腫瘤療效。聚合物奈米顆粒和膠束等技術的發展已被證明有利於藥物遞送。因此，在預測期內，加強對Sorafenib的研究力度，以提高生物有效性並減少其副作用，對市場而言是一個重要的機會。

然而，獲得性抗藥性、經濟負擔、副作用等諸多因素限制了癌症患者從Sorafenib中獲得健康益處。高昂的價格也是限制Sorafenib使用的主要因素之一。人們認為，Sorafenib的高昂價格與其帶來的實質益處不符。

此外，已知Sorafenib會對接受該藥物治療的癌症患者產生多種副作用，因此製藥公司正忙於開發新藥和藥物組合，以期在未來取代Sorafenib。新治療方法的開發對Sorafenib的銷售構成了嚴峻挑戰。

目錄

第1章 引言

  • 市場定義
  • 市場區隔
  • 調查時間表
  • 先決條件
  • 限制

第2章調查方法

  • 資料探勘
  • 二次調查
  • 初步調查
  • 專家建議
  • 品質檢查
  • 最終審核
  • 數據三角測量
  • 自下而上的方法
  • 自上而下的方法
  • 調查流程

第3章執行摘要

  • 市場概況
  • 全球Sorafenib市場區域分析（CAGR）
  • 全球Sorafenib產品市場
  • 全球Sorafenib市場（按應用）
  • 未來市場機遇
  • 全球市場區隔

第4章 市場展望

  • Sorafenib尼全球市場前景
  • 市場促進因素
    • 癌症患者增加
  • 市場限制
    • 阻礙更多患者受益於Sorafenib的因素
    • Sorafenib相關的健康風險
  • 市場機遇
    • 正在進行的研究旨在開發有效的Sorafenib製劑
  • 市場挑戰
    • Sorafenib銷售下滑
    • 新型替代藥物的出現
  • COVID-19 對Sorafenib市場的影響

第5章 按產品分類的市場

  • 概述
  • 專利藥品
  • 學名藥

第6章 按應用分類的市場

  • 概述
  • 腎癌
  • 肝癌
  • 甲狀腺癌
  • 其他

第7章 區域市場

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 其他亞太地區
  • 世界其他地區
    • 中東和非洲
    • 拉丁美洲

第8章競爭格局

  • 概述
  • 企業市場排名分析

第9章：公司簡介

  • BAYER AG
  • CIPLA
  • NATCO PHARMA
  • HETERO HEALTHCARE
Product Code: 78956

Sorafenib Market Size And Forecast

Sorafenib Market was valued at USD 1.11 Billion in 2024 and is projected to reach USD 1.21 Billion by 2031, growing at a CAGR of 1.21% from 2024 to 2031.

Sorafenib is primarily used in the treatment of renal cancer (kidney cancer), thyroid cancer, and liver cancer. The incidence of thyroid cancer has been increasing over the last few decades according to epidemiological research findings. Sorafenib Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Sorafenib Market Definition

Sorafenib is a type of molecular targeted cancer drug that works by inhibiting multiple kinases thought to be involved in both cell proliferation (growth) and angiogenesis (blood supply). Sorafenib was initially developed to treat patients with unresectable hepatocellular carcinoma (HCC), patients with advanced renal cell carcinoma, and patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.

The oral kinase inhibitor drug is effective in regulating various protein kinases and signal transduction pathways including the signal transducer and activator of transcription 3 (STAT3), platelet-derived growth factor receptor (PDGFR), and vascular endothelial growth factor receptor 2 (VEGFR-2). Sorafenib is also been used in treating liver and thyroid cancer. The drug is used as a first-line treatment for advanced hepatocellular carcinoma (HCC).

However, sorafenib treatment has not been widely adopted into oncology practice since FDA approval in 2007. The drug is known to present several side effects including, hemorrhage, hypertension, dermatologic toxicities, cardiac ischemia and/or infarction, gastrointestinal perforation, drug-induced hepatitis, wound healing complications, and many others. Furthermore, as per various studies it has been observed that sorafenib tends to induce acquired resistance among patients that lowers its clinical importance in the field of cancer. Therefore, sorafenib is used as a combination therapy with other cytotoxic agents for HCC resulting in additive anticancer activity.

Global Sorafenib Market Overview

Cancer remains among the leading causes of death worldwide. The rate of new cancer patients is on a constant rise. Cancer is a significant public health issue and is now considered as a potentially chronic disease. Advancements in the early diagnosis and treatments have significantly improved the cancer survival rate.

Sorafenib is primarily used in the treatment of renal cancer (kidney cancer), thyroid cancer, and liver cancer. The incidence of thyroid cancer has been increasing over the last few decades according to epidemiological research findings. The incidence of thyroid cancer in higher-income countries has been considerably rising and the global age-standardized incidence rate of thyroid cancer increased by approximately 20%. Similarly, with the surge in the liver and kidney cancer cases, the demand for anti-cancer drugs such as sorafenib is expected to rise.

Scientists are unleashing the potential of nanotechnology to improve sorafenib's targetability and bioavailability. Sorafenib-based nano delivery systems allow controlled release of the drug for better anti-tumor effects. Similarly, various research studies are underway incorporating the application of polymer micelles to enhance the antitumor effect of sorafenib. The development of polymer nanoparticles, micelles, and others are proving beneficial for drug delivery. Therefore, it can be suggested that the growing research studies on sorafenib to improve its bioavailability with fewer side effects present a great opportunity for the market over the forecast period.

However, there are several factors such as - acquired resistance, economic burden, adverse reaction, and others are limiting cancer patients to gain health benefits from Sorafenib. Also, the high price has been one of the major factors behind the limited use of Sorafenib. People find the high cost of Sorafenib does not justify enough benefit offered by the drug.

Furthermore, as Sorafenib is known to cause several side effects to the cancer patients receiving the drug, pharmaceutical manufacturing companies are busy developing new drugs or drug combinations that can potentially substitute Sorafenib in the future. The development of new drug treatment approaches poses a strong challenge to the Sorafenib sales

Global Sorafenib Market: Segmentation Analysis

The Global Sorafenib Market is segmented on the basis of Product, Application, and Geography.

Sorafenib Market, By Product

Patented Drugs

Generic Drugs

On the basis of Product, the Global Sorafenib Market has been segmented into Patented Drugs and Generic Drugs. Patented Drugs accounted for the largest market share in 2019. In the case of Sorafenib, in 2008 Bayer was granted a patent over Sorafenib Tosylate (marketed as Nexavar). This crucial drug for kidney and liver cancer was sold at a price that was not affordable in select regions, this factor, along with the general popularity of the drug propelled the growth of generic Sorafenib drugs, particularly in the Asia Pacific region.

Sorafenib Market, By Application

Kidney Cancer

Liver Cancer

Thyroid Cancer

Based on Application, the market is bifurcated into Kidney Cancer, Liver Cancer, Thyroid Cancer, Other. Kidney Cancer accounted for the largest market share in 2019 as Nexavar (sorafenib) has shown to be an effective treatment option for renal cell carcinoma (RCC), or kidney cancer. Researchers from Europe and the United States recently conducted a subgroup analysis of the Treatment Approach in Renal Cancer Global Evaluation Trial. This trial was a large clinical trial evaluating Nexavar in the treatment of advanced RCC.

Sorafenib Market, By Geography

North America

Europe

Asia Pacific

Rest of the world

On the basis of regional analysis, the Global Sorafenib Market is classified into North America, Europe, Asia Pacific, and Rest of the World (RoW). North America dominated the Sorafenib market in 2019 owing to the high prevalence of liver cancer, early diagnosis of liver cancer, availability of cancer therapeutic drugs, high levels of awareness about liver cancer in the region. Also, the well-established health care infrastructure in this region is expected to contribute to the dominant share of North America in the global market.

Key Players

The "Global Sorafenib Market" study report will provide a valuable insight with an emphasis on the global market including some of the major players such as Bayer AG, Cipla, Natco Pharma, and Hetero Healthcare Ltd.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 MARKET DEFINITION
  • 1.2 MARKET SEGMENTATION
  • 1.3 RESEARCH TIMELINES
  • 1.4 ASSUMPTIONS
  • 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

  • 2.1 DATA MINING
  • 2.2 SECONDARY RESEARCH
  • 2.3 PRIMARY RESEARCH
  • 2.4 SUBJECT MATTER EXPERT ADVICE
  • 2.5 QUALITY CHECK
  • 2.6 FINAL REVIEW
  • 2.7 DATA TRIANGULATION
  • 2.8 BOTTOM-UP APPROACH
  • 2.9 TOP DOWN APPROACH
  • 2.1 RESEARCH FLOW

3 EXECUTIVE SUMMARY

  • 3.1 MARKET OVERVIEW
  • 3.2 GLOBAL SORAFENIB MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
  • 3.3 GLOBAL SORAFENIB MARKET, BY PRODUCT (USD MILLION)
  • 3.4 GLOBAL SORAFENIB MARKET, BY APPLICATION (USD MILLION)
  • 3.5 FUTURE MARKET OPPORTUNITIES
  • 3.6 GLOBAL MARKET SPLIT

4 MARKET OUTLOOK

  • 4.1 GLOBAL SORAFENIB MARKET OUTLOOK
  • 4.2 MARKET DRIVERS
    • 4.2.1 RISING PREVALENCE OF PATIENTS SUFFERING WITH CANCER
  • 4.3 MARKET RESTRAINTS
    • 4.3.1 FACTORS PREVENTING MORE PATIENTS BENEFITTING FROM SORAFENIB
    • 4.3.2 HEALTH RISKS ASSOCIATED WITH SORAFENIB
  • 4.4 MARKET OPPORTUNITY
    • 4.4.1 ONGOING RESEARCH STUDIES FOR THE DEVELOPMENT OF EFFECTIVE SORAFENIB FORMULATIONS
  • 4.5 MARKET CHALLENGES
    • 4.5.1 DECREASING SALES OF SORAFENIB
    • 4.5.2 EMERGENCE OF NEW SUBSTITUTE DRUGS
  • 4.6 IMPACT OF COVID-19 ON SORAFENIB MARKET

5 MARKET, BY PRODUCT

  • 5.1 OVERVIEW
  • 5.2 PATENTED DRUGS
  • 5.3 GENERIC DRUGS

6 MARKET, BY APPLICATION

  • 6.1 OVERVIEW
  • 6.2 KIDNEY CANCER
  • 6.3 LIVER CANCER
  • 6.4 THYROID CANCER
  • 6.5 OTHERS

7 MARKET, BY GEOGRAPHY

  • 7.1 OVERVIEW
  • 7.2 NORTH AMERICA
    • 7.2.1 U.S.
    • 7.2.2 CANADA
    • 7.2.3 MEXICO
  • 7.3 EUROPE
    • 7.3.1 GERMANY
    • 7.3.2 U.K.
    • 7.3.3 FRANCE
    • 7.3.4 REST OF EUROPE
  • 7.4 ASIA PACIFIC
    • 7.4.1 CHINA
    • 7.4.2 INDIA
    • 7.4.3 JAPAN
    • 7.4.4 REST OF ASIA PACIFIC
  • 7.5 REST OF WORLD
    • 7.5.1 MIDDLE EAST AND AFRICA
    • 7.5.2 LATIN AMERICA

8 COMPETITIVE LANDSCAPE

  • 8.1 OVERVIEW
  • 8.2 COMPANY MARKET RANKING ANALYSIS

9 COMPANY PROFILES

  • 9.1 BAYER AG
    • 9.1.1 COMPANY OVERVIEW
    • 9.1.2 COMPANY INSIGHTS
    • 9.1.3 SEGMENT BREAKDOWN
    • 9.1.4 PRODUCT BENCHMARKING
    • 9.1.5 SWOT ANALYSIS
  • 9.2 CIPLA
    • 9.2.1 COMPANY OVERVIEW
    • 9.2.2 COMPANY INSIGHTS
    • 9.2.3 SEGMENT BREAKDOWN
    • 9.2.4 PRODUCT BENCHMARKING
    • 9.2.5 SWOT ANALYSIS
  • 9.3 NATCO PHARMA
    • 9.3.1 COMPANY OVERVIEW
    • 9.3.2 COMPANY INSIGHTS
    • 9.3.3 SEGMENT BREAKDOWN
    • 9.3.4 PRODUCT BENCHMARKING
    • 9.3.5 SWOT ANALYSIS
  • 9.4 HETERO HEALTHCARE
    • 9.4.1 COMPANY OVERVIEW
    • 9.4.2 COMPANY INSIGHTS
    • 9.4.3 PRODUCT BENCHMARKING
    • 9.4.4 SWOT ANALYSIS

LIST OF TABLES

  • TABLE 1 GLOBAL SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 2 GLOBAL SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 3 GLOBAL SORAFENIB MARKET, BY GEOGRAPHY, 2020 - 2027 (USD MILLION)
  • TABLE 4 NORTH AMERICA SORAFENIB MARKET, BY COUNTRY, 2020 - 2027 (USD MILLION)
  • TABLE 5 NORTH AMERICA SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 6 NORTH AMERICA SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 7 U.S. SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 8 U.S. SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 10 CANADA SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 11 CANADA SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 13 MEXICO SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 14 MEXICO SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 16 EUROPE SORAFENIB MARKET, BY COUNTRY, 2020 - 2027 (USD MILLION)
  • TABLE 17 EUROPE SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 18 EUROPE SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 19 GERMANY SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 20 GERMANY SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 21 U.K. SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 22 U.K. SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 23 FRANCE SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 24 FRANCE SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 25 REST OF EUROPE SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 26 REST OF EUROPE SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 27 ASIA PACIFIC SORAFENIB MARKET, BY COUNTRY, 2020 - 2027 (USD MILLION)
  • TABLE 28 ASIA PACIFIC SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 29 ASIA PACIFIC SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 30 CHINA SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 31 CHINA SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 32 INDIA SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 33 INDIA SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 34 JAPAN SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 35 JAPAN SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 36 REST OF ASIA PACIFIC SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 37 REST OF ASIA PACIFIC SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 38 REST OF WORLD SORAFENIB MARKET, BY REGION, 2020 - 2027 (USD MILLION)
  • TABLE 39 REST OF WORLD SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 40 REST OF WORLD SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 41 MIDDLE EAST AND AFRICA SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 42 MIDDLE EAST AND AFRICA SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 43 LATIN AMERICA SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 44 LATIN AMERICA SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 45 COMPANY MARKET RANKING ANALYSIS
  • TABLE 46 BAYER AG: PRODUCT BENCHMARKING
  • TABLE 47 CIPLA: PRODUCT BENCHMARKING
  • TABLE 48 NATCO PHARMA: PRODUCT BENCHMARKING
  • TABLE 49 HETERO HEALTHCARE: PRODUCT BENCHMARKING

LIST OF FIGURES

  • FIGURE 1 GLOBAL SORAFENIB MARKET SEGMENTATION
  • FIGURE 2 RESEARCH TIMELINES
  • FIGURE 3 DATA TRIANGULATION
  • FIGURE 4 MARKET RESEARCH FLOW
  • FIGURE 5 GLOBAL SORAFENIB MARKET OVERVIEW
  • FIGURE 6 GLOBAL SORAFENIB MARKET GEOGRAPHICAL ANALYSIS, 2020-2027
  • FIGURE 7 GLOBAL SORAFENIB MARKET, BY PRODUCT (USD MILLION)
  • FIGURE 8 GLOBAL SORAFENIB MARKET, BY APPLICATION (USD MILLION)
  • FIGURE 9 FUTURE MARKET OPPORTUNITIES
  • FIGURE 10 NORTH AMERICA DOMINATED THE MARKET IN 2019
  • FIGURE 11 GLOBAL SORAFENIB MARKET OUTLOOK
  • FIGURE 12 GLOBAL AGE-STANDARDIZED INCIDENCE RATES OF CANCER IN 2018
  • FIGURE 13 GLOBAL NUMBER OF NEW CASES IN 2018, BOTH SEXES, ALL AGES
  • FIGURE 14 BAYER - NEXAVAR / SORAFENIB SALES
  • FIGURE 15 GLOBAL SORAFENIB MARKET, BY PRODUCT
  • FIGURE 16 GLOBAL SORAFENIB MARKET, BY APPLICATION
  • FIGURE 17 GLOBAL SORAFENIB MARKET, BY GEOGRAPHY, 2020 - 2027 (USD MILLION)
  • FIGURE 18 NORTH AMERICA MARKET SNAPSHOT
  • FIGURE 19 EUROPE MARKET SNAPSHOT
  • FIGURE 20 ASIA PACIFIC MARKET SNAPSHOT
  • FIGURE 21 REST OF WORLD SNAPSHOT
  • FIGURE 22 BAYER AG: COMPANY INSIGHT
  • FIGURE 23 BAYER AG: SEGMENT BREAKDOWN
  • FIGURE 24 BAYER AG: SWOT ANALYSIS
  • FIGURE 25 CIPLA: COMPANY INSIGHTS
  • FIGURE 26 CIPLA: SEGMENT BREAKDOWN
  • FIGURE 27 CIPLA: SWOT ANALYSIS
  • FIGURE 28 NATCO PHARMA: COMPANY INSIGHTS
  • FIGURE 29 NATCO PHARMA: SEGMENT BREAKDOWN
  • FIGURE 30 NATCO PHARMA: SWOT ANALYSIS
  • FIGURE 31 HETERO HEALTHCARE: COMPANY INSIGHT
  • FIGURE 32 HETERO HEALTHCARE: SWOT ANALYSIS